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Abstract The gold standard for evaluating cognitive impair-
ments in HIV-infected patients is to administer an extensive
neuropsychological assessment. This may, however, be time-
consuming and hence not always feasible in the clinic.
Therefore, several brief screening tools have been developed.
This study determined the validity of the Montreal Cognitive
Assessment (MoCA) and the HIV Dementia Scale (HDS) in
detecting cognitive impairment using both the Frascati and
cognitive impairment, no dementia (CIND) criteria to classify
cognitive impairment in HIV-1 infected patients. The MoCA,
HDS, and an extensive neuropsychological assessment, cov-
ering nine cognitive domains, were administered in a group of
102 HIV-infected patients who were all on cARTand virolog-
ically suppressed for at least 1 year. Results show that the
areas under the curve (AUCs) for both the MoCA and the
HDS were statistically significant, using both the Frascati
and the CIND criteria as gold standard. However, the AUCs
for the MoCA and HDS did not differ significantly, regardless
of the used classification criteria (Frascati: z=0.37, p=0.35;
CIND: z=−0.62, p=0.27). Sensitivity of both the MoCA and
HDS were low for the recommended cutoff scores (Frascati:
MoCA (<26)=0.56, HDS (<11)=0.26; CIND: MoCA (<26)=
0.55, HDS (<11)=0.36). Cutoff scores with good sensitivity
and adequate specificity could not be determined for both
screening instruments. Therefore, the HDS and MoCA are
not recommended as sole instruments to diagnose HIV-
associated cognitive impairment.
Keywords HIV/AIDS . Cognitive impairment . Screening
tool . MoCA . HDS
Introduction
The incidence of severe HIV-associated cognitive impairment
has significantly declined since the introduction of combina-
tion antiretroviral therapy (cART), while milder forms of cog-
nitive decrements continue to be prevalent and increase with
age. Recent results from the CHARTER study demonstrated
that 44 % of HIV-infected patients on cART, without marked
comorbidities, fulfilled the criteria for milder forms of HIV-
associated neurocognitive disorder (HAND) (Heaton et al.
2010). These neurocognitive impairments may have a great
impact on functioning in vocational settings or on academic
achievements. Furthermore, cognitively impaired patients are
at greater risk of poor medication adherence (Hinkin et al.
2004).
The gold standard for adequately evaluating cognitive im-
pairments is to administer an extensive neuropsychological
assessment, as this method has a high sensitivity and specific-
ity. A neuropsychological assessment typically covers a range
of cognitive domains, such as memory, executive functioning,
and attention, and can be used to classify levels of cognitive
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dysfunction in HIV using the widely used revised HAND
criteria, referred to as the Frascati criteria (Heaton et al.
2010; Antinori et al. 2007). Patients are classified as asymp-
tomatic or mildly impaired when they show a performance
that lies 1 standard deviation (SD) below the demographically
adjusted normative mean, yet within 2 SD in at least two
cognitive domains. When a patient obtains a score of at least
2 SDs below the mean within at least two cognitive domains,
he or she is classified as severely impaired. Gisslén et al.
(2011) pointed out, however, that a cutoff of −1 SD to classify
impairment may lead to overestimation of the real prevalence
of cognitive impairment. That is, given the normal distribu-
tion, 15.9 % of any population will perform worse than 1 SD
below the normative mean on a given test. Another way to
determine cognitive impairment is to use the criteria Bcognitive
impairment, no dementia^ (CIND). Patients are classified as
having CIND when one or more of the cognitive domains are
impaired, which may result in less false positives (Van den
Berg et al. 2005). The CIND criteria define impairment as an
average performance >1 on the tasks in a cognitive domain (a
score of 0 is obtained when the performance is in the normal
range (−1 SD to 1 SD), a score of 1 when the performance is
below average (−1 SD to −1.65 SD) and a score of 2 when the
performance is impaired (less than −1.65 SD). The CIND
criteria are somewhat more stringent because they require at
least one of the test scores in a cognitive domain to be lower
than −1 SD to be classified as impaired.
The problem with extensive neuropsychological testing,
however, is that it is often time-consuming and requires
trained personnel to administer, score, and interpret (Koski
et al. 2011; Overton et al. 2013). To overcome this limitation,
several brief screening tools to detect cognitive impairment in
HIV-infected patients have been developed over the years
(Valcour et al. 2011). An example of such a short screening
test is the HIV Dementia Scale (HDS) (Power et al. 1995).
This test consists of items addressing memory, attention, psy-
chomotor functioning, and visuoconstruction. The HDS has
been shown to be an adequate screening tool in HIV-infected
patients in detecting severe cognitive impairment, but has
been shown to be insensitive to milder forms of cognitive
deficits (Valcour et al. 2011; Bottigi et al. 2007; Carey et al.
2004; Zipursky et al. 2013).
Another widely used screening method to detect cognitive
impairment is the Montreal Cognitive Assessment (MoCA)
(Nasreddine et al. 2005). This screening test takes approxi-
mately 10–15 min to administer and consists of 30 items mea-
suring eight cognitive domains. The MoCA is sensitive in
differentiating milder forms of cognitive impairments and
has been validated in patients with Parkinson’s disease,
Huntington’s disease, substance abuse, and mild cognitive
impairment (MCI) (Freitas et al. 2012; Larner 2012;
Videnovic et al. 2010; Zadikoff et al. 2008; Wester et al.
2013; Thissen et al. 2010). However, to date, few studies have
investigated the validity of theMoCA inHIV-infected patients
(Koski et al. 2011; Overton et al. 2013; Hasbun et al. 2012;
Milanini et al. 2014). Most studies used the Frascati criteria to
classify cognitive impairment and none of these studies have
directly compared the widely known HDS to the MoCA. Ours
is the first study that investigates the validity of theMoCA and
the HDS in HIV-infected patients in relation to two sorts of
clinical criteria to determine cognitive impairment.
The current study focused on a cohort of HIV-infected pa-
tients who were all on cART and virologically suppressed for
at least 1 year. The primary objective of this study was to
determine the validity of the MoCA and the HDS in detecting
cognitive impairment as measured with an extensive neuro-
psychological test battery, and impairment classified with both
the Frascati criteria and the CIND criteria. Sensitivity, speci-
ficity, and areas under the curve (AUCs) of the HDS and the
MoCA were assessed. Furthermore, we aimed to determine
sensitive and specific cutoff scores for both the MoCA and
the HDS.
Methods
Participants
A total of 102 HIV-1 infected patients were included between
January 16, 2012 and January 31, 2014. Consecutive patients
were recruited through their treating physicians via the outpa-
tient clinic for infectious diseases at the Department of Internal
Medicine in the Radboud University Medical Center in
Nijmegen and at the same department in the Rijnstate
Hospital Arnhem. Patients were eligible if they were between
18 and 70 years old, fluent speaker of the Dutch language, had
no current drug or alcohol addiction, and no history of psy-
chiatric or neurological disorder (unrelated to HIV-1 infection
in the patients). Inclusion criteria were an HIV-1 infection and
absence of active opportunistic infections, pregnancy, malig-
nancy, and neurosyphilis. HIV status of all patients was deter-
mined by enzyme-linked immunosorbent assays (ELISA) and
a Western blot confirmatory test. Patients were selected re-
gardless of the presence of signs or symptoms of suspected
cognitive impairment or subjective cognitive complaints.
Medical ethical approval was obtained for this study, and
written informed consent was obtained from all participants.
Neuropsychological assessment
Participants completed an extensive neuropsychological test
battery measuring nine major cognitive domains. Tests that
are sensitive to measure small or moderate differences in abil-
ity were chosen and were administered by trained neuropsy-
chologists. The allocation of tests to the domains was made a
priori, according to standard neuropsychological practice,
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psychometric properties of the tests, and cognitive theory
(Lezak et al. 2012). Also, the domains and tests were based
on previous studies that examined cognitive impairment in
HIV-infected patients (Heaton et al. 2010; Janssen et al. 2013).
Abstract reasoning was assessed by the Raven Advanced
ProgressiveMatrices (12-item short form) (Raven et al. 1993).
Language was assessed with a letter fluency tasks (BK-O-M^;
1 min per letter) (Schmand et al. 2008). The domain Speed of
information processing included the Digit-Symbol
Substitution subtest from the WAIS-III, the Trail Making
Test part A (TMT-A), and the Stroop Color-Word Test (cards
I and II) (Wechsler 1955; Reitan 1958; Rey 1964; Stroop
1935). Learning was assessed both verbally and nonverbally
with the Dutch version of the Rey Auditory Verbal Learning
Test (RAVLT, immediate memory: total score on trials 1–5)
and the Location Learning Test–Revised (LLT-R, immediate
memory: total score on trials 1–5), respectively (Rey 1964;
Bucks et al. 2011). The domain Memory was also assessed
verbally and nonverbally with the same tasks as the domain
Learning with the delayed recall trial of both tasks. Executive
function consisted of three subdomains: Concept shifting,
Planning, and Response inhibition. Shifting was measured
with the Brixton Spatial Anticipation Test and with the inter-
ference score of the Trail Making Test part B (TMT-B)
(Burgess and Shallice 1997; Reitan 1958). Planning was
assessed with the Zoo Map test from the Behavioural
Assessment of the Dysexecutive Syndrome (BADS) (Wilson
et al. 2003). Response inhibition was assessed by the Stroop
Color-Word Test (Stroop 1935). Here, the Stroop interference
score was computed, using the following formula: (time need-
ed for card III−time needed for card II)/time needed for card
II) (Stuss et al. 2001). Attention/Working memory was mea-
sured with the 2.0 and 1.6 interstimulus interval (ISI) trials of
the Paced Auditory Serial Addition Test (PASAT) (60 items
per trial), the Letter-Number Sequencing subtest from the
Wechsler Adult Intelligence Scale, third edition (WAIS-III),
and the Corsi Block Tapping task (Aarnoudse et al. 1995;
Wechsler 1955; Kessels et al. 2000). The domain Motor
function was measured with the Grooved Pegboard Test (ad-
ministered for the dominant and nondominant hand) (Heaton
et al. 1992). Finally, Visuoconstructionwas measured with the
copy trial of the Rey-Osterrieth Complex Figure Test (Rey
1941).
Symptom validity was measured with the short version of
the Amsterdam Short-Term Memory Test (ASTM) (cutoff
score <42) (Schmand et al. 1999). To assess whether patients
had subjective cognitive complaints, all participants complet-
ed the Cognitive Failures Questionnaire (CFQ; Broadbent
et al. 1982), using a cutoff score of 1.65 SD above the
age-adjusted normative mean for the CFQ total score (Ponds
et al. 2006). Education level was recorded using seven cate-
gories in agreement with the Dutch educational system
(1=less than primary school; 7=academic degree). These
levels match closely to the following categories in year of
education as used in the Anglo-Saxon world (Bouma et al.
2012; Oosterman et al. 2014): level 1, incomplete primary
education 1–5 years; level 2, primary education 6 years; level
3, incomplete lower secondary education 7–8 years; level 4,
lower general secondary education 7–9 years; level 5, voca-
tional education 7–10 years; level 6, higher general secondary/
higher vocational/pre-university education 7–16 years; and
level 7, academic degree 17–20 years. Premorbid intellectual
level (estimated IQ) was estimated with the Dutch version of
the National Adult Reading Test (Schmand et al. 1992).
Montreal Cognitive Assessment
Each participant completed the Dutch version of the MoCA
(Nasreddine et al. 2005). The MoCA consists of 13 tasks
measuring the following eight cognitive domains: visuospa-
tial/executive, naming, memory, attention, language, abstrac-
tion, delayed recall, and orientation. TheMoCA takes approx-
imately 10–15 min to complete. A total score was calculated
by summing scores of the 13 tasks. The maximum score pos-
sible is 30 points, with a cutoff score of ≤26 indicative of
cognitive impairment. One point was added for each partici-
pant with 12 or fewer years of formal education.
HIV Dementia Scale
Each participant also completed the HDS (Power et al. 1995).
This test consists of four items measuring four cognitive do-
mains including memory, attention, motor speed, and
visuoconstruction. A total score was calculated by summing
scores of the four items, with a maximum score of 16. A score
of <11 gives an indication of cognitive impairment.
Data analysis
Neuropsychological impairments were classified per task
using age- and education-adjusted normative data (i.e., using
1 SD and 1.65 SD below the normative mean as cutoff scores
for mild and severe impairment, respectively) (Bouma et al.
2012; Lezak et al. 2012; Van den Berg et al. 2005). The per-
formance on the neuropsychological assessment as a whole
was classified as either Bimpaired^ or Bunimpaired^ for each
patient using both the Frascati and CIND criteria. In the
Frascati criteria, impairment of 1 SD below the normative
mean must to be present in at least two domains for a partic-
ipant to be classified as Bcognitively impaired.^ Furthermore,
at least one of the ability deficits has to be outside the motor
and sensory perceptual domain, in agreement with the updated
nosology for HIV-associated neurocognitive disorders by
Antinori et al. (2007). Performance on the CFQ was used to
classify cognitively impaired patients in accordance with the
Frascati criteria as having asymptomatic neurocognitive
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impairment (ANI; i.e., no subjective complaints, yet mild im-
pairments on cognitive testing) or mild neurocognitive disor-
der (MND; i.e., both subjective complaints and mild impair-
ments on cognitive testing). None of the patient fulfilled the
criteria for HIV-associated dementia (HAD; i.e., all patients
functioned independently at home).
Using the CIND criteria, a patient’s performance was clas-
sified as cognitively impaired if impairments were present in
one or more of the individual cognitive domains. Performance
on each test was rated as within the normal range (0), below
average (1), or impaired (2). A score between −1 SD and 1 SD
was defined as normal performance, a score between −1 SD
and −1.65 SD asmildly impaired, and a score below −1.65 SD
as impaired. A cognitive domain was classified as impaired
when the average rating of tests in that domain was >1 (Van
den berg et al. 2005).
In agreement with Woods et al. (2003), a performance be-
low the cutoff of a symptom validity test is likely not the result
of actual HIV-associated cognitive impairment and must
therefore be regarded as an indication of underperformance
due to suboptimal effort. Participants performing below this
cutoff were removed from the statistical analyses.
Data were analyzed by using IBM SPSS version 19.0.
Receiver operating characteristic (ROC) analyses were per-
formed with the MoCA and the HDS as continuous variables
and cognitive impairment, classified with both the Frascati
and the CIND criteria, as state variable. The AUC was deter-
mined for each ROC curve, and cutoff scores for both screen-
ing tools were determined that had good sensitivity accompa-
nied with an acceptable specificity. A cutoff score was defined
as adequate if a sensitivity of >0.8 was accompanied by an
acceptably low false-positive rate (specificity >0.6) (Blake
et al. 2002).
Results
Three patients performed below the cutoff of the symptom
validity test and were removed from the analyses.
Furthermore, two patients dropped out due to medical reasons
unrelated to HIV status (recent CVA and severe epilepsy) and
two due to missing data (in one patient, not all tests could be
completed due to an eye condition, in another patient the
MoCA could not be administered because it was accidentally
missing in the test battery). The total sample therefore
consisted of 95 HIV-1 infected patients. Table 1 shows rele-
vant demographic characteristics and the scores on the MoCA
and HDS. Mean age of the patients was 48.2 years. The mean
nadir CD4 cell count was 213 cells/mm3 (IQR 100, 305) with
all patients virologically suppressed on cART (<50
copies/mL). Using the Frascati criteria, 39 of the 95 patients
(41.1 %) were classified as cognitively impaired. When the
CIND criteria were applied, 22 of the 95 patients (23.2%)were
classified as cognitively impaired. The MoCA identified 33 of
the 95 patients (34.7 %) as cognitively impaired, while the
HDS identified 12 of 95 (12.6 %) patients with cognitive
impairment, using the clinically established cutoff scores.
Table 2 shows neuropsychological performance scores and
impairments for the cognitive domains and all the tests in
the neuropsychological assessment.
Figure 1a, b shows the AUCs of the ROC analyses for the
MoCA and the HDS in classifying cognitive impairment as
measured with the extensive neuropsychological assessment,
with impairment classified with both the Frascati and the
CIND criteria in HIV-1-infected patients. All AUCs were sta-
tistically significant (Frascati: MoCA AUC=0.70, CI=0.59–
0.80, p=0.001; HDS AUC=0.67, CI=0.56–0.79, p=0.005;
CIND: MoCA AUC=0.66, CI=0.52–0.80, p=0.024; HDS
AUC=0.72, CI=0.58–0.86, p=0.002). Different cutoff scores
with the accompanying sensitivity and specificity for cogni-
tive impairment are shown for both screening instruments and
the two different criteria to classify cognitive impairment in
Table 3. Cutoff scores with good sensitivity (>0.8) and an
acceptable specificity (>0.6) could not be determined, howev-
er. The clinically established cutoff scores resulted in the fol-
lowing sensitivity (Se) and specificity (Sp) for the MoCA
(<26) and HDS (<11) (Frascati: MoCA Se=0.56, Sp =0.63;
HDS Se=0.26, Sp =0.96; CIND: MoCA Se=0.55, Sp =0.58;
HDS Se=0.36, Sp =0.95). Using a cutoff of 27 for the MoCA
Table 1 Demographic variables and performance on the MoCA and
HDS
Characteristic HIV-infected patients
(N=95)
Age (years) [mean (SD)] 48.2 (10.1)
Sex 83 (87.4 %) male
12 (12.6 %) female
Nadir CD4 cell count (cells/μL) [mean (IQR)] 213 (100–305)
Duration HIV infection (years) [mean (SD)] 9.83 (6.3)
Duration cART treatment (years) [mean (SD)] 8.44 (5.7)
Education level (median)a 6
Estimated IQ [mean (SD)] 98.2 (13.9)
Cognitive impairment cf. Frascati 39 (41.1 %)
Asymptomatic neurocognitive impairment
(ANI)
34 (35.8 %)
Mild neurocognitive disorder (MND) 5 (5.3 %)
HIV-associated dementia (HAD) 0 (0 %)
Cognitive impairment cf. CIND 22 (23.2 %)
MoCA score [mean (SD)] 26.6 (2.3)
MoCA < cutoff 33 (34.7 %)
HDS score [mean (SD)] 13.8 (2.3)
HDS < cutoff 12 (12.6 %)
a Education level was recorded using seven categories that can be trans-
ferred to years of education: 1, 1–5 years; 2, 6 years; 3, 7–8 years; 4, 7–
9 years; 5, 7–10 years; 6, 7–17 years; and 7, >18 years
386 J. Neurovirol. (2015) 21:383–390
slightly increased the sensitivity to 0.74 when the level of
impairment was classified using the Frascati and to 0.64 when
the CIND criteria were used. Also, the sensitivity of the HDS
could be improved to 0.67 and 0.77 when a cutoff score of 14
was applied, for classification according to the Frascati and
CIND criteria, respectively. The specificity of these cutoff
scores remained low, however (0.41–0.61). Statistical com-
parison of the ROC curves for the two screening instruments
using both the Frascati and the CIND criteria shows that the
ROC curves did not differ significantly (Frascati: z=0.025,
CI=−0.10–0.15, p=0.69; CIND: z=−0.064, CI=−0.22–0.10,
p=0.43).
Discussion
This study examined the validity of the MoCA and HDS in
relation to classification of cognitive impairment using both
the Frascati and CIND criteria in a Dutch group of HIV-
infected patients. With respect to discriminating patients with
and without cognitive impairments classified using both the
Frascati and the CIND criteria, the AUCs for both the MoCA
and the HDS were statistically significant. Cutoff scores with
both good sensitivity accompanied with a respectable speci-
ficity could not be determined, however. Furthermore, the
AUCs for the MoCA and the HDS did not differ significantly
regardless of the scoring criteria.
The proportion of HIV-infected individuals with cognitive
impairments identified using the Frascati criteria (41.1 %) is
similar to previous estimates of 33.3 and 52 % reported by
Tozzi et al. (2003) and Heaton et al. (2010), respectively.
When the more stringent CIND criteria are used, a much lower
proportion of the patients was classified as being cognitively
impaired (23.2 %). Using the current Frascati guidelines, the
milder forms of HAND (MND and ANI) are defined by a
performance 1 SD below the mean of normative scores in at
least two domains. As mentioned previously, about 16 % of
the normal population will by definition perform worse than 1
SD below the mean on a given test. In other words, around
16 % of a normal population will be classified as impaired
when the Frascati criteria are used, which is an unacceptable
false-positive rate (that is, 2–5 % is generally considered ac-
ceptable) (Lezak et al. 2012). Overestimation of the preva-
lence of HAND due to liberal classification criteria obscures
the actual extent of cognitive deficits in HIV-infected individ-
uals (Gisslén et al. 2011). Therefore, using more stringent
criteria to determine cognitive impairment must be recom-
mended. Alternative criteria to determine cognitive impair-
ment in HIV-infected patients, first suggested in this study,
are the CIND criteria. These criteria define impairment as an
average performance >1 on the tasks in a cognitive domain.
To obtain a score of >1 on a given domain, at least one of the
tasks in that domain has to be severely impaired. The CIND
criteria are therefore more stringent then the Frascati criteria.
These might be used as an alternative to the Frascati criteria in
classifying HIV-related neurocognitive impairment.
As noted previously, for both the MoCA and HDS, good
sensitivity and specificity could not be found in distinguishing
cognitively impaired from cognitively unimpaired patients.
The sensitivity for both the MoCA and HDS was particularly
low for the recommended cutoff scores when either the
Frascati or CIND criteria were used to classify cognitive im-
pairment. The sensitivity increased slightly when the thresh-
olds for the MoCA and the HDS were raised, yet their spec-
ificity remained low, indicating a high risk of false-positive
results. The current findings for the HDS are in line with
previous studies who demonstrated poor prognostic values
Table 2 Neuropsychological performance: impairments on the
cognitive domains and on each test per cognitive domain
Cognitive domains and tests Mean (±SD) N (%)
impaired
Abstract reasoning −0.38 (±1.03) 0 (0)
Raven Advanced Progressive Matrices 9.09 (±2.30) 0 (0)
Language −0.05 (±1.02) 7 (7.4)
Letter Fluency Test (BK-O-M^) 40.13 (±13.20) 7 (7.4)
Speed of information processing −0.11 (±0.80) 2 (2.1)
WAIS-III Digit-Symbol substitution 69.32 (±14.19) 10 (10.5)
TMT-A 30.54 (±9.98) 1 (1.1)
Stroop I and II 51.34 (±8.46) 1 (1.1)
Learning −0.04 (±0.88) 5 (5.3)
RAVLT (total trials 1–5) 43.22 (±9.28) 10 (10.5)
LLT-R (total trials 1–5) 14.97 (±14.45) 2 (2.1)
Memory 0.00 (±0.77) 3 (3.2)
RAVLT (delayed recall) 8.69 (±3.02) 9 (9.5)
LLT-R (delayed recall) 0.64 (±1.68) 3 (3.2)
Executive functioning −0.07 (±0.68) 0 (0)
Brixton 40.11 (±5.82) 1 (1.1
TMT-B 70.28 (±27.23) 4 (4.2)
BADS Zoo Map Test 11.38 (±4.10) 11 (11.6)
Stroop (interference) 0.61 (±0.33) 5 (5.3)
Attention/working memory −0.09 (±0.71) 3 (3.2)
PASAT 32.44 (±9.39) 27 (28.4)
Corsi Block Tapping task (span forward
and backward)
6.14 (±0.69) 0 (0)
WAIS-III Letter-Number Sequencing 11.12 (±3.20) 3 (3.2)
Motor −0.09 (±0.89) 3 (3.2)
Pegboard ( dominant and nondominant) 79.26 (±12.48) 3 (3.2)
Visuoconstruction −0.10 (±1.03) 7 (7.4)
Rey Complex Figure-copy 33.72 (±3.23) 7 (7.4)
Domain scores are presented as mean z scores±SD; individual test scores
are presented asmean raw scores±SD. Cognitive domains were classified
as impairedwhen a score of less than −1.65 SDwas obtained inmore than
half of the tasks in that domain. Test scores were classified as impaired
when a score of less than −1.65 SD was obtained on the age- and
education-adjusted score
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using the HDS to detect mild impairment in HIV-infected
patients (Valcour et al. 2011; Bottigi et al. 2007; Zipursky
et al. 2013). This screening tool was originally developed to
detect HIV-associated dementia, and the performance charac-
teristics to detect severe forms of cognitive impairment are
modest to good (Berghuis et al. 1999). Morgan et al. (2008)
showed that performance could be improved by adjusting for
age and education, but the sensitivity remains modest (0.70)
even after adjustment. To our knowledge, there are only a few
studies that extensively investigated the validity of the MoCA
in HIV-infected patients. Recent research of Overton et al.
(2013) who also used extensive neuropsychological testing
found somewhat higher sensitivity scores for the MoCA com-
pared to the current study, but with comparable specificity
levels. Another recent study by Milanini et al. (2014) found
higher sensitivity and specificity levels than the current study,
but investigated an older population of patients over 60 years.
A study by Hasbun et al. (2012) showed moderate diagnostic
accuracy for theMoCA (sensitivity 85%, specificity 40%). In
contrast to the current study, the latter investigated ART-naive
HIV-infected patients with high viral loads and high levels of
comorbitities (hepatitis B and C), active drug use, depression,
and unemployment. Koski et al. (2011) reported that the
MoCA adequately measures cognitive ability as a global con-
struct using Rasch analyses but showed poorer precision for
measuring patients with higher cognitive ability. That is, half
of the MoCA items were too easy for their high-functioning
sample, resulting in ceiling performance. These items there-
fore contributed little to the measurement of overall cognitive
ability in this group.
Regardless of the criteria used to classify the neuropsycho-
logical performance, milder forms of cognitive impairments
continue to exist in a substantial amount of HIV-infected pa-
tients. Given the impact that these impairments may have on
daily functioning and quality of life, the need for effective
Fig. 1 aROC curves for theMoCA and HDS using several cutoff points in comparison with cognitive impairment classified with the Frascati criteria. b
ROC curves for the MoCA and HDS using several cutoff points in comparison with cognitive impairment classified with the CIND criteria
Table 3 Cutoff points
with different degrees of
sensitivity and specificity
for the MoCA and HDS
in the identification of
cognitive impairment
using extensive
neuropsychological
assessment classified
with the Frascati and
CIND criteria
Cutoff Sensitivity Specificity
Frascati criteria
MoCA
25.5 0.51 0.77
26.5 0.56 0.63
27.5 0.74 0.50
28.5 0.92 0.36
HDS
11.25 0.26 0.96
13.75 0.49 0.77
14.25 0.67 0.61
14.75 0.69 0.50
15.25 0.80 0.38
CIND criteria
MoCA
25.5 0.55 0.71
26.5 0.55 0.58
27.5 0.64 0.41
28.5 0.91 0.29
HDS
11.25 0.36 0.95
13.75 0.59 0.74
14.25 0.77 0.58
14.75 0.77 0.48
15.25 0.82 0.34
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screening instruments to identify these patients remains high.
Our study shows that simple tools developed for HIV-
associated dementia are suboptimal in discriminating current
HIV-infected populations. More comprehensive screening
tools, like the MoCA, show mixed results in the literature. In
our study, the validity of the MoCAwas about similar to that
of the HDS, but respectable sensitivity and specificity of this
screening tool has been demonstrated for other patient groups.
Sensitivity levels could be improved when the cutoff scores
were increased, but the specificity levels remained low. A high
sensitivity might be preferred in the clinical practice; however,
combined with a low specificity, the risk of identifying pa-
tients without cognitive impairments as Bimpaired^ is high.
As a result, these tools are not recommended for use in the
diagnostic process.
Our study was the first to investigate the validity of the
MoCA in comparison with the HDS. Furthermore, unlike pre-
vious studies that have investigated the validity of MoCA and
the HDS in HIV-infected patients, ours is the first that used
both the Frascati and CIND criteria to classify cognitive im-
pairment. Strengths of the study are the use of an extensive
neuropsychological test battery in comparison to the short
cognitive screening tools and the application of a symptom
validity test. In order to obtain monetary compensation and/or
service benefits, some patients might feign or exaggerate their
neuropsychological deficits (Woods et al. 2003). Symptom
validity tests are designed to be passable for all but the most
severely impaired patients, given that the participant has pro-
vided adequate mental effort in the task. Also, this study had
several limitations. Only HIV-infected patients who were on
cART and were virologically suppressed for at least 1 year
were included. These inclusion criteria were deliberately set
to reduce the influence of other potentially confounding fac-
tors that may be present in uncontrolled HIV-infected patients,
such as hepatitis B or C, syphilis, or malignancy. While our
sample is representative for the majority of HIV-infected pa-
tients in the Netherlands (Van Sighem et al. 2013), to investi-
gate detailed performance characteristics of cognitive screen-
ing instruments, a more heterogeneous group of patients with
respect to severity of cognitive deficits might show better
results. Secondly, although all patients were living indepen-
dently at home and none fulfilled the criteria for dementia, we
did not formally assess activities of daily living.
In sum, our study showed moderate sensitivity combined
with poor specificity in detecting cognitive impairment with
the MoCA and the HDS in HIV-infected patients, using both
the widely applied Frascati criteria and the more stringent
CIND criteria to classify cognitive impairment. On the basis
of the present results, we cannot recommend these tools for
the assessment of HIV-associated cognitive impairment.
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